Description
This book offers an in-depth exploration of pharmacogenetics as applied to antiplatelet therapies, highlighting how genetic variations influence response to these drugs. The first section introduces the fundamentals of pharmacogenetics. The second part focuses on aspirin and variations in clinical response. Subsequent sections analyze P2Y12 receptor inhibitors, exploring individual responses influenced by genetic polymorphisms. The book also covers other classes of antiplatelet agents, such as phosphodiesterase inhibitors, glycoprotein IIb IIIa inhibitors, and protease-activated receptor inhibitors.In conclusion, the book assesses the impact of adjusting antiplatelet therapies based on genetic test results, offering an informed perspective on the potential benefits of precision medicine in the management of cardiovascular disease.
